NEORAL Drug Patent Profile

Which patents cover Neoral, and when can generic versions of Neoral launch?

Neoral is a drug marketed by Novartis and is included in two NDAs.

The generic ingredient in NEORAL is cyclosporine. There are eighteen drug master file entries for this compound. Twenty suppliers are listed for this compound. Additional details are available on the cyclosporine profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Neoral

A generic version of NEORAL was approved as cyclosporine by HIKMA on October 29^th, 1999.

Summary for NEORAL

US Patents:	0
Applicants:	1
NDAs:	2
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	1
Clinical Trials:	129
Patent Applications:	4,625
Drug Prices:	Drug price information for NEORAL
What excipients (inactive ingredients) are in NEORAL?	NEORAL excipients list
DailyMed Link:	NEORAL at DailyMed

See drug prices for NEORAL

Recent Clinical Trials for NEORAL

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Fred Hutchinson Cancer Center	Phase 2
National Cord Blood Network	Phase 2
Erasmus Medical Center	N/A

See all NEORAL clinical trials

Pharmacology for NEORAL

Drug Class	Calcineurin Inhibitor Immunosuppressant
Mechanism of Action	Calcineurin Inhibitors Cytochrome P450 3A4 Inhibitors P-Glycoprotein Inhibitors

US Patents and Regulatory Information for NEORAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	NEORAL	cyclosporine	CAPSULE;ORAL	050715-001	Jul 14, 1995	AB1	RX	Yes	No
Novartis	NEORAL	cyclosporine	SOLUTION;ORAL	050716-001	Jul 14, 1995	AB1	RX	Yes	Yes
Novartis	NEORAL	cyclosporine	CAPSULE;ORAL	050715-003	Jul 14, 1995		DISCN	Yes	No
Novartis	NEORAL	cyclosporine	CAPSULE;ORAL	050715-002	Jul 14, 1995	AB1	RX	Yes	Yes

Expired US Patents for NEORAL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Novartis	NEORAL	cyclosporine	CAPSULE;ORAL	050715-003	Jul 14, 1995	5,962,014
Novartis	NEORAL	cyclosporine	CAPSULE;ORAL	050715-002	Jul 14, 1995	5,342,625
Novartis	NEORAL	cyclosporine	SOLUTION;ORAL	050716-001	Jul 14, 1995	6,024,978
Novartis	NEORAL	cyclosporine	SOLUTION;ORAL	050716-001	Jul 14, 1995	5,342,625
Novartis	NEORAL	cyclosporine	CAPSULE;ORAL	050715-003	Jul 14, 1995	5,342,625

International Patents for NEORAL

See the table below for patents covering NEORAL around the world.

Country	Patent Number	Title	Estimated Expiration
Greece	3032366
South Korea	0148748
China	1079907
Japan	2653958
Taiwan	438609

Supplementary Protection Certificates for NEORAL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2049079	LUC00006	Luxembourg		PRODUCT NAME: CYCLOSPORINE (GOUTTES OCULAIRES SOUS FORME D'EMULSION); AUTHORISATION NUMBER AND DATE: EU/1/15/990 20150323

NEORAL: Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

NEORAL, the brand name for cyclosporine oral solution, generated $1.1 billion in revenue for Novartis in 2002. The drug's primary indication is the prevention of organ rejection in kidney, liver, and heart transplant patients. It also treats severe cases of psoriasis and rheumatoid arthritis. The market for NEORAL is characterized by established competition and the looming threat of generic entry, impacting its future revenue streams and profitability.

What is NEORAL's Market Position?

NEORAL's market position is defined by its established efficacy in transplant medicine and its significant use in dermatological and rheumatological indications.

Transplant Market Share

NEORAL has historically held a dominant position in the immunosuppressant market for organ transplantation. In 2002, it represented a substantial portion of Novartis's pharmaceutical sales, underscoring its importance in this therapeutic area. The drug's ability to reduce the risk of acute and chronic rejection is well-documented, leading to its widespread adoption post-transplant.

Non-Transplant Indications

Beyond transplantation, NEORAL is prescribed for severe psoriasis and rheumatoid arthritis. These indications represent a secondary but significant revenue stream. The drug's mechanism of action, which modulates the immune system, is beneficial in managing these autoimmune conditions.

Competitive Landscape

The immunosuppressant market is highly competitive. NEORAL faces competition from other calcineurin inhibitors, such as tacrolimus (Prograf, Advagraf), and a range of newer immunosuppressive agents targeting different pathways. These competitors offer alternative treatment options, some with different side-effect profiles or dosing regimens, influencing physician prescribing patterns and market share.

Patent Expirations and Generic Competition

The patent portfolio surrounding NEORAL has been a critical factor in its market trajectory. Key patents for cyclosporine have expired in major markets, opening the door for generic manufacturers. The introduction of generic cyclosporine products has demonstrably impacted NEORAL's pricing power and market share.

What are NEORAL's Financial Performance Metrics?

NEORAL's financial performance has been shaped by its initial success, patent expiries, and the evolving competitive environment.

Revenue Generation

Novartis reported global sales for NEORAL reaching approximately $1.1 billion in 2002. This figure highlights the drug's peak revenue-generating capacity before significant generic penetration. Subsequent annual reports show a decline in dedicated NEORAL sales as generic alternatives gained traction.

Profitability and Margins

As a branded product with established clinical data, NEORAL likely commanded premium pricing, contributing to healthy profit margins during its exclusivity period. However, with generic competition, pricing pressure intensifies, leading to reduced profitability for the branded product and potentially lower overall revenue contribution to Novartis.

R&D Investment

While NEORAL itself is a mature product, ongoing R&D investment by Novartis may have focused on lifecycle management, such as developing improved formulations or exploring new indications, though primary innovation efforts have likely shifted to newer drug candidates.

Market Penetration by Generics

The penetration of generic cyclosporine has been a primary driver of NEORAL's declining sales trajectory post-patent expiry. Generic manufacturers can offer their products at significantly lower price points, making them attractive alternatives for healthcare providers and payers.

What are the Future Market Projections for NEORAL?

The future market for NEORAL is projected to be characterized by continued market share erosion due to generic competition and a sustained but reduced role in its established indications.

Impact of Generic Substitution

The primary factor influencing NEORAL's future market is the ongoing impact of generic cyclosporine. As more generic options become available and gain regulatory approval in various countries, the market share for the branded NEORAL is expected to continue to decrease. This trend is typical for branded pharmaceuticals once their primary patents expire.

Pricing Dynamics

Generic competition invariably leads to downward price pressure. The price of NEORAL will likely face continued reductions to remain competitive against lower-cost generic alternatives. This will directly affect the overall revenue generated by the product.

Market Size Estimates

Quantifying the precise future market size for NEORAL is challenging due to the increasing substitutability with generics. However, the overall market for cyclosporine as an active pharmaceutical ingredient will persist, driven by its therapeutic utility. The branded NEORAL's contribution to this market will diminish.

Novaris's Strategic Response

Novartis's strategy concerning NEORAL will likely involve managing the decline of the branded product while focusing R&D and commercial efforts on newer, patent-protected assets. This may include maximizing remaining patent life, if any, through specific market strategies or focusing on regions where generic entry is slower. The company's portfolio diversification also mitigates the impact of declining sales of individual mature products.

What are the Key Risks and Opportunities?

NEORAL faces significant risks from generic competition but also has opportunities in specific market segments and potential for continued use based on its established profile.

Risks

• Generic Erosion: The most significant risk is the continued loss of market share and pricing power due to the availability of lower-cost generic cyclosporine. This directly impacts revenue and profitability.
• Therapeutic Advancements: The development of novel immunosuppressive agents with improved efficacy, safety profiles, or convenience could further reduce the demand for NEORAL and its generics.
• Payer Policies: Increasing pressure from healthcare payers to utilize the most cost-effective treatment options can accelerate the shift towards generic cyclosporine.
• Regulatory Changes: Evolving regulatory landscapes regarding drug approvals and market exclusivity could impact pricing and market access for both branded and generic versions.

Opportunities

• Established Clinical Profile: NEORAL possesses a long history of clinical use and a well-understood efficacy and safety profile, which can foster continued physician trust and prescribing, particularly in complex cases.
• Geographic Markets: In certain emerging markets, patent protection may be stronger or generic entry slower, allowing the branded NEORAL to maintain a larger market share for a longer period.
• Specific Patient Populations: For certain patient populations or in specific treatment protocols where NEORAL has demonstrated superior outcomes or tolerability, physicians may continue to prefer the branded product even with generic alternatives available.
• Lifecycle Management (Limited): While major patent expiries have occurred, any remaining intellectual property on specific formulations or manufacturing processes could offer limited opportunities for differentiation or extended exclusivity in niche applications.

Key Takeaways

• NEORAL generated $1.1 billion in revenue for Novartis in 2002, primarily for transplant rejection prevention.
• The drug also treats severe psoriasis and rheumatoid arthritis.
• Key patents for cyclosporine have expired, leading to significant generic competition.
• Generic entry has resulted in substantial market share erosion and pricing pressure for branded NEORAL.
• Future market performance will be dominated by generic substitution, with the branded product's revenue expected to continue declining.
• Risks include ongoing generic erosion and the emergence of superior therapeutic alternatives.
• Opportunities lie in its established clinical profile, potential for continued use in specific patient populations, and market presence in regions with slower generic adoption.

Frequently Asked Questions

1. When did the primary patents for NEORAL expire in major markets? The primary patents for cyclosporine, the active ingredient in NEORAL, began expiring in major markets like the United States and Europe in the early to mid-2000s, facilitating the entry of generic versions.

2. What are the main therapeutic areas where NEORAL is used? NEORAL is primarily used to prevent organ rejection in kidney, liver, and heart transplant recipients. It is also indicated for severe cases of psoriasis and rheumatoid arthritis.

3. How has generic competition impacted NEORAL's pricing? Generic competition has led to significant downward pressure on the pricing of NEORAL, as manufacturers of generic cyclosporine offer their products at substantially lower costs.

4. What is Novartis's current strategy regarding NEORAL? Novartis is likely managing the decline of the branded NEORAL product and focusing its strategic and R&D efforts on newer, patent-protected pharmaceuticals, rather than investing heavily in lifecycle management for NEORAL.

5. Can NEORAL still be prescribed by physicians despite the availability of generics? Yes, physicians can still prescribe branded NEORAL. Prescribing decisions are based on factors such as physician preference, patient history, clinical efficacy, formulary availability, and cost considerations, though the economic incentive increasingly favors generics.

Citations

[1] Novartis AG. (2003). Novartis Annual Report 2002. Retrieved from [Novartis Investor Relations archives or financial databases]. [2] Generic pharmaceutical market analysis reports. (Various years). Data compiled from industry intelligence services tracking drug sales and patent expiries. [3] Food and Drug Administration (FDA). (Ongoing). Drug approval databases and patent information. [4] European Medicines Agency (EMA). (Ongoing). Drug approval databases and patent information. [5] Transplant immunology and rheumatology clinical practice guidelines. (Various publications). Journals such as The Lancet, New England Journal of Medicine, American Journal of Transplantation.